• 1
    Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001;8 (5):283301.
  • 2
    Laroux FS. Mechanisms of inflammation: the good, the bad and the ugly. Front Biosci 2004;9: 315662.
  • 3
    Cotran RS. Robbins Pathologic Basis of Disease, 5th edn. Philadelphia: W.B. Saunders Company;1994.
  • 4
    Fazio VW, Jones IT. Standard Surgical treatment of Crohn's disease of small intestine and ileocolitis. In: LeeECG, NolanDJ, editors. Surgery of Inflammatory Bowel Disease. Edinburgh: Churchill Livingstone;1987: 823848.
  • 5
    Weakley FL, Turnbull RB. Recognition of regional ileitis in the operating room. Dis Colon Rectum 1971;14 (1):1723.
  • 6
    Borley NR, Mortensen NJ, Jewell DP, Warren BF. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000;190 (2):196202.
  • 7
    Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79 (9):9558.
  • 8
    Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117 (1):7381.
  • 9
    Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27 (11):98791.
  • 10
    Boydstun JS Jr, Gaffey TA, Bartholomew LG. Clinicopathologic study of nonspecific ulcers of the small intestine. Dig Dis Sci 1981;26 (10):9116.
  • 11
    Lawrason FD, Alpert E, Mohr FL, McMahon FG. Ulcerative-obstructive lesions of the small intestine. JAMA 1965;191: 6414.
  • 12
    Englmeier KH, Herpers R, Jacoby RS, Zwiebel FM. A method for the estimation of the hemoglobin distribution in gastroscopic images. Int J Biomed Comput 1996;41 (3):15365.
  • 13
    Pereira JM, Sirlin CB, Pinto PS, Casola G. CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics 2005;25 (1):6985.
  • 14
    Hulten L, Lindhagen J, Lundgren O, Fasth S, Ahren C. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 1977;72 (3):38896.
  • 15
    Bacaner MB. Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology 1966;51 (5):76477.
  • 16
    Ludwig D, Schwarting K, Korbel CM, Bruning A, Schiefer B, Stange EF. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 1998;28 (4):6318.
  • 17
    McLean A. Transabdominal bowel sonography in Crohn's disease. Gut 1999;44 (1):67.
  • 18
    Muller AF. Role of duplex Doppler ultrasound in the assessment of patients with post-prandial abdominal pain. Gut 1992;33 (4):4605.
  • 19
    Maconi G, Parente F, Bollani S, Cesana B, Bianchi PG. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996;91 (8):16049.
  • 20
    Maconi G, Imbesi V, Bianchi PG. Doppler ultrasound measurement of intestinal blood flow in inflammatory bowel disease. Scand J Gastroenterol 1996;31 (6):5903.
  • 21
    Van Oostayen JA, Wasser MN, Griffioen G, Van Hogezand RA, Lamers CB, De RA. Activity of Crohn's disease assessed by measurement of superior mesenteric artery flow with Doppler ultrasound. Neth J Med 1998;53 (6):S3S8.
  • 22
    Van Oostayen JA, Wasser MN, Griffioen G, Van Hogezand RA, Lamers CB, De RA. Diagnosis of Crohn's ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol 1998;93 (1):8891.
  • 23
    Van Oostayen JA, Wasser MN. Use of Doppler ultrasound in Crohn's disease. Gut 2000;47 (1):156.
  • 24
    Van Oostayen JA, Wasser MJ. Use of Doppler ultrasound of the SMA for Crohn's disease activity evaluation in clinical practice. Clin Radiol 2002;57 (6):537.
  • 25
    Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. Gut 1999;44 (1):1127.
  • 26
    Sonnenberg A, Erckenbrecht J, Peter P, Niederau C. Detection of Crohn's disease by ultrasound. Gastroenterology 1982;83 (2):4304.
  • 27
    Bolondi L, Gaiani S, Brignola C, Campieri M, Rigamonti A, Zironi G et al. Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol 1992;27 (6):5017.
  • 28
    May CN. Prolonged systemic and regional haemodynamic effects of intracerebroventricular angiotensin II in conscious sheep. Clin Exp Pharmacol Physiol 1996;23 (10–11):87884.
  • 29
    Iwao T, Toyonaga A, Sato M, Oho K, Sakai T, Tayama C et al. Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis. J Hepatol 1997;27 (3):48491.
  • 30
    Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci (Lond) 1992;83 (2):1718.
  • 31
    Ulrich-Baker MG, Hollwarth ME, Kvietys PR, Granger DN. Blood flow responses to small bowel resection. Am J Physiol 1986;251 (6 Part 1):G815G822.
  • 32
    Angerson WJ, Allison MC, Baxter JN, Russell RI. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut 1993;34 (11):15314.
  • 33
    Worlicek H, Lutz H, Heyder N, Matek W. Ultrasound findings in Crohn's disease and ulcerative colitis: a prospective study. J Clin Ultrasound 1987; 15 (3):15363.
  • 34
    Worlicek H. Sonography of the small and large intestine – differential diagnosis of wall thickening. Bildgebung 1987;56 (1):2734.
  • 35
    Kimmey MB, Wang KY, Haggitt RC, Mack LA, Silverstein FE. Diagnosis of inflammatory bowel disease with ultrasound: An in vitro study. Invest Radiol 1990;25 (10):108590.
  • 36
    Heyne R, Rickes S, Bock P, Schreiber S, Wermke W, Lochs H. Non-invasive evaluation of activity in inflammatory bowel disease by power Doppler sonography. Z Gastroenterol 2002;40 (3):1715.
  • 37
    Goldberg BB, Liu JB, Burns PN, Merton DA, Forsberg F. Galactose-based intravenous sonographic contrast agent: experimental studies. J Ultrasound Med 1993;12 (8):46370.
  • 38
    Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ 2001;322 (7296):12225.
  • 39
    Di Sabatino A, Fulle I, Ciccocioppo R, Ricevuti L, Tinozzi FP, Tinozzi S et al. Doppler enhancement after intravenous levovist injection in Crohn's disease. Inflamm Bowel Dis 2002;8 (4):2517.
  • 40
    Tateishi S, Arima S, Futami K. Assessment of blood flow in the small intestine by laser Doppler flowmetry: comparison of healthy small intestine and small intestine in Crohn's disease. J Gastroenterol 1997t;32 (4):45763.
  • 41
    Crohn BB, Ginsberg L, Oppenheimer GD. Regional ilietis: a clinical and pathological entity. JAMA 1932;99: 13239.
  • 42
    Futagami Y, Haruma K, Hata J, Fujimura J, Tani H, Okamoto E et al. Development and validation of an ultrasonographic activity index of Crohn's disease. Eur J Gastroenterol Hepatol 1999;11 (9):100712.
  • 43
    Limberg B, Osswald B. Diagnosis and differential diagnosis of ulcerative colitis and Crohn's disease by hydrocolonic sonography. Am J Gastroenterol 1994;89 (7):10517.
  • 44
    Reimund JM, Jung-Chaigneau E, Chamouard P, Wittersheim C, Duclos B, Baumann R. Diagnostic value of high resolution sonography in Crohn's disease and ulcerative colitis. Gastroenterol Clin Biol 1999;23 (6–7):7406.
  • 45
    Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002;21 (4):37582.
  • 46
    Laghi A, Paolantonio P, Iafrate F, Borrelli O, Dito L, Tomei E et al. MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease. Radiol Med (Torino) 2003;106 (1–2):1827.
  • 47
    Haber HP, Busch A, Ziebach R, Stern M. Bowel wall thickness measured by ultrasound as a marker of Crohn's disease activity in children. Lancet 2000;355 (9211):123940.
  • 48
    Kettritz U, Shoenut JP, Semelka RC. MR imaging of the gastrointestinal tract. Magn Reson Imaging Clin N Am 1995;3 (1):8798.
  • 49
    D’Arienzo A, Scaglione G, Bennato R, Manguso F, Vicinanza G, Belfiore G et al. The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil. Am J Gastroenterol 2001;96 (2):4816.
    Direct Link:
  • 50
    Mayer D, Reinshagen M, Mason RA, Von Muche RTC, Eckelt D, Adler G et al. Sonographic measurement of thickened bowel wall segments as a quantitative parameter for activity in inflammatory bowel disease. Z Gastroenterol 2000;38 (4):295300.
  • 51
    Risau W. Mechanisms of angiogenesis. Nature 1997;386 (6626):6714.
  • 52
    Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43: 175203.
  • 53
    Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford) 1999;38 (2):10312.
  • 54
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1 (1):2731.
  • 55
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86 (3):35364.
  • 56
    Polverini PJ. Role of the macrophage in angiogenesis-dependent diseases. EXS 1997;79: 1128.
  • 57
    Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98 (2):14757.
  • 58
    Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5 (5):495502.
  • 59
    Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 1999;237: 13358.
  • 60
    Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5 (12):135964.
  • 61
    Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE et al. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995;73 (3):33946.
  • 62
    Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang XN et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995;147 (3):56473.
  • 63
    Walsh DA, Wade M, Mapp PI, Blake DR. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 1998;152 (3):691702.
  • 64
    Walsh DA, Mapp PI. Joint physiology and synovial cell proliferation. Br J Rheumatol 1998;37 (9):10323.
  • 65
    Walsh DA, Rodway HA, Claxson A. Vascular turnover during carrageenan synovitis in the rat. Lab Invest 1998;78 (12):151321.
  • 66
    Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005;83 (2):10618.
    Direct Link:
  • 67
    Hatton MW, Southward SM, Legault KJ, Ross BL, Clarke BJ, Bajzar L et al. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin (ogen) fragments contain antiangiogenic activity. J Lab Clin Med 2004;143 (4):24154.
  • 68
    Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003;95 (22):166073.
  • 69
    Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D et al. Generation of biologically active angiostatin kringle 1–3 by activated human neutrophils. J Immunol 2002;168 (11):5798804.
  • 70
    Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Huang Y, Osdoby P. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 2002;17 (10):185971.
  • 71
    Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004; 93 (1):3943.
  • 72
    Okada F. Inflammation and free radicals in tumor development and progression. Redox Rep 2002;7 (6):35768.
  • 73
    Crivellato E, Ribatti D. Involvement of mast cells in angiogenesis and chronic inflammation. Curr Drug Targets Inflamm Allergy 2005;4 (1):911.
  • 74
    Milkiewicz M, Brown MD, Egginton S, Hudlicka O. Association between shear stress, angiogenesis, and VEGF in skeletal muscles in vivo. Microcirculation 2001;8 (4):22941.
  • 75
    Cullen JP, Sayeed S, Sawai RS, Theodorakis NG, Cahill PA, Sitzmann JV et al. Pulsatile flow-induced angiogenesis: role of G (i) subunits. Arterioscler Thromb Vasc Biol 2002;22 (10):16106.
  • 76
    Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003;23 (7):114351.
  • 77
    Saito S, Tsuno NH, Sunami E, Hori N, Kitayama J, Kazama S et al. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 2003;38 (3):22937.
  • 78
    Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001;96 (3):8228.
  • 79
    Danese S, Sans M, Spencer D, Beck I, Plunkett M, Donate F et al. Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis. Gastroenterology 2005;128 (4): A-40 (Abstract).
  • 80
    Stupack DG, Storgard CM, Cheresh DA. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res 1999;32 (5):57381.
  • 81
    Jackson JR, Bolognese B, Kircher CH, Marshall LA, Winkler JD. Modulation of angiogenesis in a model of chronic inflammation. Inflamm Res 1997;46 (Suppl. 2):S12930.
  • 82
    Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32 (9):106573.
  • 83
    Funayama Y, Sasaki I, Naito H, Fukushima K, Matsuno S, Masuda T. Remodeling of vascular wall in Crohn's disease. Dig Dis Sci 1999;44 (11):231923.
  • 84
    Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 100 (5 Part 1):127987.
  • 85
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC. Restoring vascular nitric oxide formation by 1-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32 (5):133644.
  • 86
    Kerstein MD. The non-healing leg ulcer: peripheral vascular disease, chronic venous insufficiency, and ischemic vasculitis. Ostomy Wound Manage 1996;42 (10A Suppl.):19S35S.
  • 87
    Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for non-healing wounds in patients with limb ischemia. The Mayo Clinic experience (1998–2000). Int Angiol 2002;21 (4):3606.
  • 88
    Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet Med 1992;9 (4):3209.
  • 89
    Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47 (3):45763.
  • 90
    Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003;20 (4):25568.
  • 91
    Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125 (1):5869.
  • 92
    Mori M, Stokes KY, Vowinkel T, Watanabe N, Elrod JW, Harris NR et al. Colonic blood flow responses in experimental colitis: time-course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol 2005; in press.
  • 93
    Binion DG, West GA, Volk EE, Drazba JA, Ziats NP, Petras RE et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352 (9142):17426.
  • 94
    Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 2000;29 (9):8818.
  • 95
    Binion DG, Fu S, Ramanujam KS, Chai YC, Dweik RA, Drazba JA et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 1998;275 (3 Part 1):G592603.
  • 96
    Haynes WG, Davenport AP, Webb DJ. Endothelin: progress in pharmacology and physiology. Trends Pharmacol Sci 1993;14 (6):2258.
  • 97
    Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46 (3):325415.
  • 98
    Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992;339 (8790):3815.
  • 99
    Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5 (1):4460.
  • 100
    Hamilton MI, Dick R, Crawford L, Thompson NP, Pounder RE, Wakefield AJ. Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet 1995;345 (8951):68890.
  • 101
    Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2 (8671):105762.
  • 102
    Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95 (2):35967.
  • 103
    Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106 (6):145566.
  • 104
    Klemm P, Warner TD, Corder R, Vane JR. Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J Cardiovasc Pharmacol 1995;26 (Suppl. 3):S41921.
  • 105
    Warner TD, Klemm P. What turns on the endothelins? Inflamm Res 1996;45 (2):513.
  • 106
    Rachmilewitz D, Eliakim R, Ackerman Z, Karmeli F. Colonic endothelin-1 immunoreactivity in active ulcerative colitis. Lancet 1992;339 (8800):1062.
  • 107
    Inagaki H, Bishop AE, Yura J, Polak JM. Localization of endothelin-1 and its binding sites to the nervous system of the human colon. J Cardiovasc Pharmacol 1991;17 (Suppl. 7):S4557.
  • 108
    Inagaki H, Bishop AE, Escrig C, Wharton J, Len-Mersh TG, Polak JM. Localization of endothelin like immunoreactivity and endothelin binding sites in human colon. Gastroenterology 1991;101 (1):4754.
  • 109
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72 (8):29948.
  • 110
    Clapp N, Henke M, Hansard R, Carson R, Walsh R, Widomski D et al. Inflammatory mediator changes in cotton-top tamarins (CTT) after SC-41930 anti-colitic therapy. Agents Actions 1993;39: C810.
  • 111
    Clapp N, Henke M, Hansard R, Carson R, Fretland D. Anti-colitic efficacy of SC-41930 in colitic cotton-top tamarins. Agents Actions 1993;39: C368.
  • 112
    Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats: Similarity to human inflammatory bowel disease. Gastroenterology 1985;88 (1 Part 1): 5563.
  • 113
    Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990;98 (2):26977.
  • 114
    Kitsukawa Y, Saito H, Suzuki Y, Kasanuki J, Tamura Y, Yoshida S. Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs. Gastroenterology 1992;102 (6):185966.
  • 115
    Zifroni A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983;24 (7):65964.
  • 116
    Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease – pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993;7 (4):35767.
  • 117
    Boughton-Smith NK, Hawkey CJ, Whittle BJ. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut 1983;24 (12):117682.
  • 118
    Boughton-Smith NK, Whittle BJ. Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti-inflammatory agents. Br J Pharmacol 1983;78 (1):17380.
  • 119
    Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985;30 (12):11615.
  • 120
    Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 1985;89 (5):116288.
  • 121
    Hawkey CJ. Gastroduodenal problems associated with non-steroidal, anti-inflammatory drugs (NSAIDs). Scand J Gastroenterol Suppl 1993;200: 945.
  • 122
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988;29 (10):131621.
  • 123
    Lauritsen K, Rask-Madsen J. Prostaglandin analogues. Baillieres Clin Gastroenterol 1988;2 (3):6218.
  • 124
    Lauritsen K, Staerk LL, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988;29 (7):97482.
  • 125
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988;95 (1):117.
  • 126
    Kitchen EA, Boot JR, Dawson W. Chemotactic activity of thromboxane B2, prostaglandins and their metabolites for polymorphonuclear leucocytes. Prostaglandins 1978;16 (2):23944.
  • 127
    Goldman G, Welbourn R, Valeri CR, Shepro D, Hechtman HB. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. Microvasc Res 1991;41 (3):36775.
  • 128
    Wiles ME, Welbourn R, Goldman G, Hechtman HB, Shepro D. Thromboxane-induced neutrophil adhesion to pulmonary microvascular and aortic endothelium is regulated by CD18. Inflammation 1991;15 (3):18199.
  • 129
    Doukas J, Hechtman HB, Shepro D. Endothelial-secreted arachidonic acid metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro. Blood 1988;71 (3):7719.
  • 130
    Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O et al. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 1993;178 (5):182530.
  • 131
    Kelly JP, Johnson MC, Parker CW. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol 1979;122 (4):156371.
  • 132
    Zipser RD, Patterson JB, Kao HW, Hauser CJ, Locke R. Hypersensitive prostaglandin and thromboxane response to hormones in rabbit colitis. Am J Physiol 1985;249 (4 Part 1):G45763.
  • 133
    Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M et al. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992;21 (2):12733.
  • 134
    Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107 (4):5136.
  • 135
    Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J 1981;57 (667):2979.
  • 136
    Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1984;288 (6412):238.
  • 137
    Pearson DJ, Stones NA, Bentley SJ. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. Br Med J (Clin Res Ed) 1983;287 (6406):1675.
  • 138
    Rutherford D, Stockdill G, Hamer-Hodges DW, Ferguson A. Proctocolitis induced by salicylate. Br Med J (Clin Res Ed) 1984;288 (6419):794.
  • 139
    Shanahan F, Targan S. Sulfasalazine and salicylate-induced exacerbation of ulcerative colitis. N Engl J Med 1987;317 (7):455.
  • 140
    Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992;152 (3):62532.
  • 141
    Schwartz HA. Lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs. J Rheumatol 1981;8 (6):9524.
  • 142
    Bjarnason I, Zanelli G, Smith T, Smethurst P, Price AB, Gumpel MJ et al. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol Suppl 1987;64: 5562.
  • 143
    Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93 (3):4809.
  • 144
    Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984;25 (12):1399413.
  • 145
    Rampton DS, Barton TP. Are prostaglandins cytoprotective in the human large intestine? The effect of indomethacin on rectal mucosal function and prostaglandin E2 release in vivo. Agents Actions 1984;14 (5–6):7158.
  • 146
    Bjarnason I, Smethurst P, Clark P, Menzies I, Levi J, Peters T. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol Suppl 1989;164: 97102.
  • 147
    Bjarnason I, Macpherson A. The changing gastrointestinal side effect profile of non-steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol Suppl 1989;163: 5664.
  • 148
    Scadding G, Bjarnason I, Brostoff J, Levi AJ, Peters TJ. Intestinal permeability to 51Cr-labelled ethylenediaminetetraacetate in food-intolerant subjects. Digestion 1989;42 (2):1049.
  • 149
    Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77 (4 Part 1):7617.
  • 150
    Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112 (3):100016.
  • 151
    De CF, Beetens J, De Chaffoy de CD, Freyne E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule – I. Biochemical profile in vitro. Thromb Haemost 1989;61 (1):3542.
  • 152
    De CF, Beetens J, Van de WA, Vercammen E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule – II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989;61 (1):439.
  • 153
    De CF, Beetens J, De Chaffoy de CD, Vercammen E, Freyne E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule. Prog Clin Biol Res 1989;301: 56772.
  • 154
    Casellas F, Papo M, Guarner F, Antolin M, Segura RM, Armengol JR et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7 (3):2216.
  • 155
    Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease – pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997;11 (2):23747.
  • 156
    Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106 (4):8405.
  • 157
    Collins CE, Benson MJ, Burnham WR, Rampton DS. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Aliment Pharmacol Ther 1996;10 (3):31520.
  • 158
    Carty E, MacEy M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14 (6):80717.